MALIGNANT MELANOMA

This study tested whether adding lenvatinib to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced melanoma that cannot be removed by surgery. Over 670 adults who had not received prior treatment for their advanced disease took …

This early-phase study tested whether adding L-NMMA to the immunotherapy drug pembrolizumab is safe for people with several advanced cancers, including melanoma, lung cancer, and others. The goal was to see if blocking a signal that protects cancer cells could help the immune sys…

This study tested whether adding lenvatinib to pembrolizumab works better than pembrolizumab alone for people with advanced melanoma that cannot be removed by surgery. It involved 131 Chinese patients who had not received prior treatment for their advanced disease. The goal was t…

This early-phase study tested a combination of two experimental drugs (vobramitamab duocarmazine and lorigerlimab) in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…

This study examined 30 people with melanoma who were taking BRAF/MEK inhibitor drugs to see how often these drugs cause retinal changes (MEKAR) and what those changes look like. Participants had regular eye exams before, during, and after treatment. The goal was to better underst…

This study looked at 132 people with advanced melanoma to see if levels of a protein called interferon-gamma (IFN-γ) in tumor tissue and blood could predict how well they would respond to first-line immunotherapy drugs. Researchers also explored whether gut bacteria play a role i…

This study looked at 14 adults with melanoma who were taking a combination of BRAF and MEK inhibitors. Researchers wanted to understand eye changes (retinopathy) that can happen as a side effect of this treatment. They used regular eye exams and imaging to track these changes ove…